Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients

Axel Schulenburg1, Wolfgang Sperr, Werner Rabitsch

  • 1Department of Medicine I, Bone Marrow Transplantation Unit, Medical University of Vienna, Vienna, Austria. axel.schulenburg@meduniwein.ac.at

Leukemia & Lymphoma
|August 9, 2005
PubMed

Insights

Continuous infusion of Amphotericin B offers a safer and faster way to treat fungal infections in patients with hematological malignancies, reducing severe side effects and nephrotoxicity.

Area of Science:

  • Mycology
  • Hematology
  • Pharmacology

Background:

  • Fungal infections pose significant risks for patients with hematological malignancies.
  • Candida and Aspergillus species are common opportunistic pathogens in this vulnerable group.
  • Amphotericin B is a primary treatment but often causes severe side effects.

Purpose of the Study:

  • To evaluate the safety and efficacy of continuous infusion Amphotericin B.
  • To compare continuous infusion with rapid infusion of Amphotericin B in neutropenic patients.

Main Methods:

  • A comparative study involving 17 patients receiving continuous infusion Amphotericin B and 10 patients receiving rapid infusion.
  • Patients had hematological malignancies and fever of unknown origin, suggesting possible fungal infection.

Main Results:

  • Continuous infusion of Amphotericin B showed no acute side effects or severe nephrotoxicity.
  • Target therapeutic doses of Amphotericin B were achieved more rapidly with continuous infusion.

Conclusions:

  • Continuous infusion Amphotericin B is a safe and effective administration method for neutropenic patients with hematological malignancies.
  • This method improves treatment delivery compared to conventional rapid infusion.